Company intelligence / Profile preview

Venthera

Palo Alto, CA, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Preliminary results from the ongoing Phase 1/2 trial of VT30/BBP‑681 show that Venthera’s topical PI3Kα inhibitor therapy for rare vascular anomalies has advanced to human studies. The trial aims to establish safety, tolerability, dosing regimen, and exploratory efficacy in patients with VMs, LMs, and VLMs driven by PIK3CA or TEK mutations. Results are still preliminary; full efficacy data have not yet been published.

Therapeutic areas: Rare DiseasesCardiovascular
Modalities: Small molecules (specifically topical PI3Kα inhibitors)
Industry: Biotech

Drug pipeline

2 assets

VT10

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

BridgeBio Pharma affiliation/support; no major external pharma partnerships disclosed

Beyond the preview

Go deeper on Venthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venthera.

Explore the full profile